Hormonal
Semaglutide 2.4 mg administered once weekly produces significant weight loss (mean 14.9%) in adults with obesity or overweight, superior to placebo, when combined with lifestyle interventions.
Semaglutide 2.4mg weekly, combined with diet and exercise, leads to substantial weight loss (approx 15%) in obese adults without diabetes. Expect potential nausea, which often subsides. It is more effective than older drugs like orlistat and requires weekly injection rather than daily.
After 68 weeks, the semaglutide group had an average weight loss of 14.9%, compared to 2.4% in the placebo group. About 86.4% of participants who received semaglutide lost at least 5% of their body weight, while only 31.5% in the placebo group reached this milestone.
Why this rating
Based on narrative review citing large RCTs (STEP 1, STEP 2) and cohort studies, but not a primary meta-analysis itself.
Source
Avaliação do reposicionamento farmacológico da semaglutida no processo de emagrecimento: Uma revisão da literatura
Juliano Policarpio Moura et al. · Research Society and Development · 2024
DOI 10.33448/rsd-v13i11.47305
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →